Nascent Biotech readies for Clinical Trials

Nascent Biotech, Inc.has raised $2.1 million which has been used to advance the development of their core product, Pritumumab, for eventual filing of an Investigation New Drug exemption (IND).  Pritumumab is a human monoclonal antibody that is being developed for the treatment of malignant and non malignant Gliomas.  One of the biggest challenges in the development of any antibody product is to show that it can be manufactured at appropriate scale, to clinical grade and in sufficient quantity for human trials.  "We have completed this and manufactured more than enough product to complete our initial Phase 1/Phase 2 human trials on Brain Cancer with more than adequate amounts left over to initiate trials in other epithelial cancers such as colon and pancreas."